Atul Deodhar
Overview
Explore the profile of Atul Deodhar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
246
Citations
5698
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
31.
Bittar M, Deodhar A
Nat Rev Rheumatol
. 2024 Feb;
20(4):201-202.
PMID: 38355843
No abstract available.
32.
Deodhar A, Blauvelt A, Lebwohl M, Feely M, Kronbergs A, Eberhart N, et al.
Arthritis Res Ther
. 2024 Feb;
26(1):49.
PMID: 38347650
Background: We report long-term, end-of-study program safety outcomes from 25 randomized clinical trials (RCTs) in adult patients with psoriasis (PsO), psoriatic arthritis (PsA), or axial spondyloarthritis (axSpA) [including ankylosing spondylitis...
33.
Mease P, Helliwell P, Gladman D, Poddubnyy D, Baraliakos X, Chakravarty S, et al.
Lancet Rheumatol
. 2024 Jan;
3(10):e715-e723.
PMID: 38287608
Background: Guselkumab was efficacious in reducing signs and symptoms of psoriatic arthritis in the phase 3 DISCOVER-1 and DISCOVER-2 studies. We aimed to evaluate the efficacy of guselkumab in post-hoc...
34.
Siebert S, Coates L, Schett G, Raychaudhuri S, Chen W, Gao S, et al.
Arthritis Rheumatol
. 2024 Jan;
76(6):894-904.
PMID: 38253404
Objective: We assessed and compared immunologic differences and associations with clinical response to guselkumab, a fully human interleukin (IL)-23p19 subunit inhibitor, in participants with active psoriatic arthritis (PsA) who were...
35.
Ermann J, Deodhar A, Khan M, Weisman M, Reveille J
Curr Rheumatol Rep
. 2024 Jan;
26(3):96-101.
PMID: 38214805
Purpose Of Review: This review takes a look at the past, present, and future of SPARTAN, the Spondyloarthritis Research and Treatment Network, an organization of North American healthcare professionals dedicated...
36.
Deodhar A, Machado P, Morup M, Taieb V, Willems D, Orme M, et al.
Rheumatology (Oxford)
. 2023 Nov;
63(5):1195-1205.
PMID: 37947318
Objectives: To compare the efficacy and safety of bimekizumab 160 mg every 4 weeks, a selective inhibitor of IL-17F and IL-17A, with those of biologic/targeted synthetic DMARDs (b/tsDMARDs) in non-radiographic...
37.
Magrey M, Cheng-Chung Wei J, Yndestad A, Bushmakin A, Cappelleri J, Dina O, et al.
Arthritis Care Res (Hoboken)
. 2023 Nov;
76(3):359-365.
PMID: 37909386
Objective: We examined the relationships of work productivity and activity impairment with key patient-reported outcomes (PROs) assessing pain, disease activity, and health-related quality of life (HRQoL) in patients with ankylosing...
38.
Strober B, Coates L, Lebwohl M, Deodhar A, Leibowitz E, Rowland K, et al.
Drug Saf
. 2023 Oct;
47(1):39-57.
PMID: 37906417
Introduction: The benefit/risk profiles of biologics can be affected by comorbidities, certain demographic characteristics, and concomitant medications; therefore, it is important to evaluate the long-term safety profiles of biologics across...
39.
Mease P, Gladman D, Poddubnyy D, Chakravarty S, Shawi M, Kollmeier A, et al.
Rheumatol Ther
. 2023 Oct;
10(6):1637-1653.
PMID: 37819505
Introduction: Guselkumab previously showed greater improvements versus placebo in axial symptoms in patients with psoriatic arthritis (PsA) (assessed by Bath Ankylosing Spondylitis Disease Activity Index [BASDAI] and Ankylosing Spondylitis Disease...
40.
Baraliakos X, Deodhar A, van der Heijde D, Magrey M, Maksymowych W, Tomita T, et al.
Ann Rheum Dis
. 2023 Oct;
83(2):199-213.
PMID: 37793792
Objectives: Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, has demonstrated superior efficacy versus placebo in patients with non-radiographic (nr-) and radiographic (r-)...